Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.30 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.30 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.30 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.30 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.30 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.30 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14002643 | 0.90 | CHRM2 (0.33) | CHRM2PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL91737 | 0.88 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL17548037 | 0.87 | HSD11B1 (0.37) | CHRM2HSD11B1 | |
| SCHEMBL14559346 | 0.87 | GRM2 (0.34) | CHRM2 | |
| SCHEMBL13447420 | 0.86 | — | — | |
| SCHEMBL21336300 | 0.85 | CHRM2 (0.33) | CHRM2TSHR | |
| SCHEMBL12333974 | 0.85 | — | — | |
| SCHEMBL9979990 | 0.85 | CHRM2 (0.33) | CHRM2 | |
| SCHEMBL13408483 | 0.85 | — | — | |
| SCHEMBL19685038 | 0.84 | PRKAB2 (0.30) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029698-A1 | ANTIOXIDANT FOR LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE USING LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2017-02-02 | — | — | US | disclosed |
| US-9487704-B2 | Nematic liquid crystal composition and liquid crystal display element using same | DIC CORPORATION (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160060526-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | DIC CORPORATION (JP) | 2016-03-03 | — | — | US | disclosed |
| WO-2012052104-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029698-A1 | ANTIOXIDANT FOR LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE USING LIQUID CRYSTAL COMPOSITION | GPX1, LPO, SCO2 | CHRM2 1164/4885HSD11B1 492/4885PRKAB2 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.